Annabidiol : Amended - 1st Quarter Ending 3/31/2021 & Disclosure Statement

AnnaBidiol Corp. dba; First Harbor Capital

A Delaware Corporation

[phone]

Amended

For the Three Months Ended March 31, 2021, and 2020

Prepared in accordance with

OTC Pink Basic Disclosure Guidelines

TABLE OF CONTENTS
	Page
Forward Looking Statements	3
Organizational Structure	3
Management	3
Balance Sheets as of March 31, 2021, and 2020	4
Statements of Operations for the Three Months Ended March 31, 2021, and 2020	5
Statement of Stockholders' Equity for the Three Months Ended March 31, 2021, and 2020	6
Statements of Cash Flows for the Three Months Ended March 31, 2021, and 2020	7
Notes to the Financial Statements	8
OTC Pink Basic Disclosures	11
Signatures	14

2

Forward-Looking Statements

This Company Profile contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements made herein that may be considered forward-looking include statements incorporating terms such as "expects," "believes," "intends," "anticipates" and similar terms that relate to future events, performance, or results of the Company, including without limitation, statements made regarding expected future results. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from management's present expectations or projections. These risks and uncertainties include, but are not limited to, customer and supplier relationships; prices; competition; ability to realize anticipated benefits from initiatives taken; market demand; litigation and other liabilities; and economic, political, governmental, and technological factors affecting the Company's operations, tax rate, markets, products, services, and prices, among others.

Organizational Structure

AnnaBidiol Corp. (the" Company" or "Asiana") was incorporated in the State of Delaware on Sept. 22, 2009, as DragonTel Holding, Inc., which after that changed its name to Asiana Dragons, Inc. The Company again changed its name to Strategic Pharma Information Sciences, Inc. on July 25, 2016, and then to AnnaBidiol Corp., effective upon FINRA approval on January 8, 2018.

Management

David D Peralta - Mr. Peralta was appointed interim Chief Executive Officer, President, and sole Director of the Company effective December 9, 2019.

3

ANNABIDIOL CORP. DBA; FIRST HARBOR CAPITAL

UNAUDITED BALANCE SHEETS

			March 31,				December 31,
			2021				2020
ASSETS
Current Assets
Cash		2,108				2,720
Total Current Assets		2,108				2,720
Total Assets
$	2,108	$	2,720
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable and accrued expenses	$	319,940	$	320,440
Total Liabilities		319,940				320,440
Commitments and Contingencies		-				-
Stockholders' Deficit
Preferred Series A, $0.0001 par value; 5,000,000 shares authorized, 500,000
shares issued and outstanding as of March 31, 2021, and December 31, 2020		50				50
Common Stock, $0.0001 par value; 495,000,000 shares authorized,
39,950,306 shares issued and outstanding as of March 31, 2021, and
December 31, 2020		3,995				3,995
Additional paid-in capital		5,265,625				5,265,625
Accumulated deficit		(5,587,502)				(5,587,390)
Total Stockholders' Deficit		(317,832)				(317,720)
Total Liabilities and Stockholders' Deficit	$	2,108			$	2,720

The accompanying notes are an integral part of these consolidated financial statements.

4

ANNABIDIOL CORP. DBA; FIRST HARBOR CAPITAL

UNAUDITED STATEMENTS OF OPERATIONS

			For the Three Months Ended
			March 31,			March 31,
			2021			2020
Revenue	$	-	$	37,470
Cost of Goods Sold			-			-
Gross Profit			-			37,470
Operating Expenses:
General administrative			112			1,113
Professional and consulting fees			-			30,000
Travel			-			-
Total operating expenses			112			31,113
Loss from operations			(112)			6,357
Other Income (Expense)
Interest expense			-			-
Total other income (expense)			-			-
Net Loss Before Income Taxes			(112)			6,357
Income tax			-			-
Net Loss After Income Taxes
$	(112)	$	6,357
Weighted Average Number of Common Shares
Outstanding - Basic and Diluted			39,950,306			39,950,306
Loss per Common Share - Basic and Diluted		$	(0.00)		$	(0.00)

The accompanying notes are an integral part of these consolidated financial statements.

5